Pharvaris FY2029 EPS Estimate Decreased by HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Investment analysts at HC Wainwright dropped their FY2029 earnings estimates for Pharvaris in a report released on Tuesday, November 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $2.19 per share for the year, down from their prior forecast of $2.22. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.10.

A number of other analysts have also recently weighed in on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. JMP Securities dropped their target price on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Bank of America upgraded Pharvaris from an “underperform” rating to a “neutral” rating and upped their price target for the stock from $16.00 to $27.00 in a report on Thursday, October 9th. Finally, Zacks Research upgraded shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and an average price target of $37.17.

Pharvaris Trading Up 7.5%

Shares of PHVS traded up $1.69 during mid-day trading on Wednesday, reaching $24.32. The company had a trading volume of 5,749 shares, compared to its average volume of 113,013. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -7.24 and a beta of -2.78. The firm has a fifty day simple moving average of $23.06 and a 200-day simple moving average of $20.54. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $26.33.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the business. Patient Square Capital LP grew its position in shares of Pharvaris by 41.4% during the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after buying an additional 101,098 shares during the last quarter. TFG Asset Management GP Ltd lifted its holdings in shares of Pharvaris by 48.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock worth $3,311,000 after purchasing an additional 61,105 shares during the last quarter. TD Asset Management Inc boosted its position in Pharvaris by 4.9% during the 3rd quarter. TD Asset Management Inc now owns 104,356 shares of the company’s stock valued at $2,604,000 after purchasing an additional 4,846 shares during the period. Geode Capital Management LLC increased its position in Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after buying an additional 15,769 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after buying an additional 7,879 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.